Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, has several upcoming catalysts to watch, including new data presentations at Digestive Disease Week (DDW) 2026, being held May 2-5, 2026, and multiple readouts and trial starts in the second half of 2026.
The company plans to present final results from its Phase 1 healthy-volunteer study of XmAb942, an extended half-life anti-TL1A antibody, at DDW 2026 in Chicago. Xencor will also share preclinical characterization data for XmAb412, a TL1A x IL23p19 bispecific antibody designed to target key inflammatory pathways in inflammatory bowel disease.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.